For the second time in under 3 weeks, the FDA has approved a treatment for the inherited genetic disorder characterized by recurrent episodes of severe swelling.

FDA approves first oral hereditary angioedema (HAE) therapy: Ekterly (sebetralstat) becomes the first and only FDA-approved oral on-demand treatment for HAE attacks in patients 12 and older. Phase III ...

BOSTON, Mass., July 07, 2025--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today ...

The FDA has approved garadacimab-gxii for prophylactic use in patients aged 12 years and older with hereditary angioedema, according to a press release from CSL Behring. The approval was based on ...

By Adriano Marchese KalVista Pharmaceuticals shares jumped in premarket trading Monday after the company said it has received regulatory approval for its treatment of hereditary angioedema.

CAMBRIDGE, Mass. & SALISBURY, England, July 07, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY ...

EKTERLY (sebetralstat), a novel plasma kallikrein inhibitor, is the first and only oral on-demand therapy approved by the U.S. FDA for the treatment of acute attacks of hereditary angioedema (HAE ...

KalVista Pharmaceuticals shares jumped in premarket trading Monday after the company said it has received regulatory approval for its treatment of hereditary angioedema.

What does a hereditary angioedema (HAE) attack look like? An HAE attack can cause swelling of body parts such as the extremities and a red rash that may look like hives.

Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life ...

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.